Phaseline

Companies › Vedanta Biosciences

Vedanta Biosciences: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Infectious disease; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
VE303
Live biotherapeutic product consisting of 8 clonally derived, nonpathogenic, nontoxigenic,
–Phase 3Clostridium DifficileJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06237452VE303Phase 3Clostridium DifficileInfectious diseaseJun 2027

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Chengdu CoenBiotech Biofabri Novavax Valneva Austria Green Cross

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.